MK-7262 Lp(a)
a phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-7262 coadministered with enlicitide in adults with elevated Lp(a)
- Stadium
- inclusie
- Middel
- MK-7262
- Populatie
- Primaire preventie coronairlijden
- Fase
- IIb
- First Patient In
- 14 september 2026
- Last Patient In
- 30 mei 2027
- Last Patient Last Visit
- -
Inclusieperiode, nog 264 dagen over
Studiedirecteur
J.M. Cheng
Cardioloog
Contact Kantoor
